Navigation Links
Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
Date:7/31/2008

U.S. AtuRNAi Patent Allowance Builds on European Equivalent Granted in

2007, Expanding Commercial Protection

LONDON, July 31 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading European RNAi focused biotechnology company, today announced that the United States Patent and Trademark Office has allowed the Company's core RNAi patent application. The Patent Office issued a 'Notice of Allowance' for patent application 10/633,630, "Interfering RNA Molecules," which covers stabilized, small interfering RNA (siRNA) molecules with defined positional modifications. The claims cover siRNA molecules that are "blunt ended," as well as molecules with one or more "overhangs" and specifically cover Silence Therapeutics' proprietary siRNA molecules, known as "AtuRNAi".

The company also announced today it has received a Notice of Acceptance from the Australian Patent Office for patent application No. 2003260370 entitled "Further novel forms of interfering RNA molecules." The European equivalent of the US and Australian patent applications was granted by the European Patent Office in January 2007.

Iain Ross, Chairman & CEO of Silence Therapeutics, said, "This is a major milestone for Silence, our partners and investors. This patent allowance protects our AtuRNAi technology and our proprietary siRNA molecules in the United States, the largest pharmaceutical market in the world. Silence already has a strong, proprietary position in the RNAi space and this allowance builds further on our global patent portfolio. With the U.S. patent allowance, we are now significantly better positioned to achieve our goal of becoming one of the leading companies in the field of RNAi therapeutics and delivery."

Silence considers its AtuRNAi to be best-in-class siRNA molecules based on important advantages over conventional siRNA molecules, including increased stability against nuclease degradation and an increased serum half-life, while ret
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Silence Therapeutics Announces Successful Opposition of Glover Patent
4. Organizational Changes at Silence Therapeutics
5. Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027
6. Silence Therapeutics Patent Update
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer ... center in the,US, the Tulane Cancer Center, ... phase III clinical study of Alpharadin in ... cancer,(CRPC) that has metastasized to the skeleton. ... (ALpharadin in SYMptomatic Prostate CAncer) study is ...
(Date:12/11/2009)... December 11, 2009 -- Esco announces the opening of a NEW ... as a technical service, training and logistics center to support Esco,s ... New Product Introductions (NPI) for temperature-controlled laboratory equipment. , ... ... opening of a NEW 2nd North American facility in Marietta, OH. ...
(Date:12/10/2009)... Institute (NEI), a division of the National Institutes of Health ... help fund its development of a non-invasive, passive diffusion-based treatment ... ... Salt Lake City, UT (PRWEB) December 10, 2009 ... National Institutes of Health (NIH), awarded a $2.18 million grant ...
(Date:12/10/2009)... of advanced flow measurement, control, and level solutions, ... as Global Level Product Manager effective November 30, ... enhance market penetration of the level measurement products ... from Lafarge Corp, a manufacturer of building materials, ... Sales. Bayda will report to Brooks Instrument Vice ...
Breaking Biology Technology:Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 2Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 3
... (Nasdaq:,CPHD) today announced the appointment of leading ... Fred Tenover, Ph.D., as,Senior Director of Scientific ... liaison,with the Infection Control community and will ... "The objective of the Cepheid HAI ...
... 9 Par,Pharmaceutical Companies, Inc. (NYSE: PRX ) ... 25mg meclizine HCl tablets immediately. At,this time, Par believes ... Par marketed meclizine prior to an explosion at ... has since qualified a new API source and,received the ...
... YARDLEY, Pa. and WOBURN, Mass., July 9 ... Business, Technology and,Regulatory strategies, and CBI Research Inc., ... executives in the pharmaceutical,and biotech industries, today announced ... will chair CBI,s "3rd Annual Manufacturing Execution,Systems for ...
Other Biology Technology:Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program 2Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program 3Par Pharmaceutical to Launch meclizine HCL Tablets 2Axendia's President to Chair 3rd Annual MES for Life Sciences Congress 2
(Date:12/14/2009)... researchers from the Astrobiology Centre (INTA-CSIC) has shown that ... the formation of the most basic biological molecules can ... to carry out this study, published in the journal ... chemical conditions of the early Earth. , "We have ... solutions it produces hydrogen cyanide, a substance that could ...
(Date:12/14/2009)... WAYNE, Pa., Dec. 14 MODA Technology ... monitoring (EM), utility and product testing for the ... MODA 3.0, the company,s third generation mobile data ... (QC) organizations to further automate their regulated manufacturing ... new capabilities: ,, Fully-Configurable Test Methods: ...
(Date:12/13/2009)... Scientists have resolved a question about how a ... works using biosensors that reveal previously hidden components ... Although delusions and hallucinations characterize the illness, people ... recall information in a particular order, difficulties that ... or function well, said Lee Schroeder, a student ...
Breaking Biology News(10 mins):Prussian blue linked to the origin of life 2MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2New biosensors reveal workings of anti-psychotic drugs in the living brain 2Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 62361 1Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 62361 2Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 62361 3Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 62361 4Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 62361 5Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 15027 1Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 15027 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 15027 3Neogen Acquires Gen Probes BioKits Food Safety Business 6639 1Neogen Acquires Gen Probes BioKits Food Safety Business 6639 2
... stand-in for humans in medical research, thanks to genomes ... behave differently in mouse and man, a study by ... Zhang reveals. , Their results, which have implications for ... appear in the current issue of the journal Proceedings ...
... Studying thousands of patients, Japanese researchers have found ... of three cancers esophageal, head and neck, and ... risk of developing these diseases. , In the May ... of the American Association for Cancer Research, scientists from ...
... bioMETRX, Inc. (OTC,Bulletin Board: BMRX) a leading developer ... has filed 5 new patent applications with,the United ... covered by the filings include tool storage chests, ... The,traditional products that are the subject of the ...
Other Biology News:Mouse can do without man's most treasured genes 2Mouse can do without man's most treasured genes 3Tooth loss strongly linked to risk of esophageal, head and neck, and lung cancer 2bioMETRX, Inc. Files for Several New Patents 2